A composition comprising at least two oligonucleotide probe sets for use in an invasive cleavage detection assay, wherein a) each probe set comprises a first and second oligonucleotide configured to form an invasive cleavage structure to detect at least a single nucleotide polymorphism in a position of a 5' UTR sequence of HCV selected from the group consisting of: -245, -167, -163, - 155, -144, -118, and -80, wherein said nucleotide positions in said 5' UTR sequence are numbered in accordance with the consensus sequences SEQ ID NOs: 64-69, and wherein - position -245 is at nucleotide 30 of SEQ ID NOs: 64-69, - position -167 is at nucleotide 108 of SEQ ID NOs: 64-69, - position -163 is at nucleotide 112 of SEQ ID NOs: 64-69, - position -155 is at nucleotide 120 of SEQ ID NOs: 64-69, - position -144 is at nucleotide 131 of SEQ ID NO: 69 and is not present in SEQ ID NOs: 64-68, - position -118 is at nucleotide 157 in SEQ ID NOs: 64-68 and nucleotide 160 in SEQ ID NO: 69 and - position -80 is at nucleotide 195 in SEQ ID NOs: 64-68 and nucleotide 198 in SEQ ID NO: 69; and b 1) said first oligonucleotide comprises a 5' portion and a 3' portion, wherein said 3' portion is configured to hybridize to said 5' UTR sequence of HCV, and wherein said 5' portion is configured to not hybridize to said 5' UTR sequence of HCV; or b 2) said second oligonucleotide comprises a 5' portion and a 3' portion, wherein said 5' portion is configured to hybridize to said 5' UTR sequence of HCV, and wherein said 3' portion is configured to not hybridize to said 5' UTR sequence of HCV. a) each probe set comprises a first and second oligonucleotide configured to form an invasive cleavage structure to detect at least a single nucleotide polymorphism in a position of a 5' UTR sequence of HCV selected from the group consisting of: -245, -167, -163, - 155, -144, -118, and -80, wherein said nucleotide positions in said 5' UTR sequence are numbered in accordance with the consensus sequences SEQ ID NOs: 64-69, and wherein - position -245 is at nucleotide 30 of SEQ ID NOs: 64-69, - position -167 is at nucleotide 108 of SEQ ID NOs: 64-69, - position -163 is at nucleotide 112 of SEQ ID NOs: 64-69, - position -155 is at nucleotide 120 of SEQ ID NOs: 64-69, - position -144 is at nucleotide 131 of SEQ ID NO: 69 and is not present in SEQ ID NOs: 64-68, - position -118 is at nucleotide 157 in SEQ ID NOs: 64-68 and nucleotide 160 in SEQ ID NO: 69 and - position -80 is at nucleotide 195 in SEQ ID NOs: 64-68 and nucleotide 198 in SEQ ID NO: 69; and - position -245 is at nucleotide 30 of SEQ ID NOs: 64-69, - position -167 is at nucleotide 108 of SEQ ID NOs: 64-69, - position -163 is at nucleotide 112 of SEQ ID NOs: 64-69, - position -155 is at nucleotide 120 of SEQ ID NOs: 64-69, - position -144 is at nucleotide 131 of SEQ ID NO: 69 and is not present in SEQ ID NOs: 64-68, - position -118 is at nucleotide 157 in SEQ ID NOs: 64-68 and nucleotide 160 in SEQ ID NO: 69 and - position -80 is at nucleotide 195 in SEQ ID NOs: 64-68 and nucleotide 198 in SEQ ID NO: 69; and b 1) said first oligonucleotide comprises a 5' portion and a 3' portion, wherein said 3' portion is configured to hybridize to said 5' UTR sequence of HCV, and wherein said 5' portion is configured to not hybridize to said 5' UTR sequence of HCV; or b 2) said second oligonucleotide comprises a 5' portion and a 3' portion, wherein said 5' portion is configured to hybridize to said 5' UTR sequence of HCV, and wherein said 3' portion is configured to not hybridize to said 5' UTR sequence of HCV.